In Halifax, Nova Scotia, on July 03, 2026, Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF), a biopharmaceutical company specializing in infectious disease drug development, disclosed the receipt of a Notice of Termination for Convenience from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH). This termination pertains to the Company’s contract for advancing the VXV-01 fungal vaccine candidate.